Asterias Biotherapeutics (NYSEAMERICAN:AST) is set to issue its quarterly earnings data after the market closes on Thursday, March 15th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.00 on Tuesday. The firm has a market capitalization of $102.89, a P/E ratio of -3.08 and a beta of 1.02. Asterias Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $4.30.
AST has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, November 22nd. Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 22nd. Finally, B. Riley initiated coverage on Asterias Biotherapeutics in a research note on Thursday, February 22nd. They issued a “buy” rating and a $6.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.94.
COPYRIGHT VIOLATION NOTICE: “Asterias Biotherapeutics (AST) Scheduled to Post Quarterly Earnings on Thursday” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3258464/asterias-biotherapeutics-ast-scheduled-to-post-quarterly-earnings-on-thursday.html.
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.